SCHEMBL2913576

SCHEMBL2913576

CCOC(=O)Nc1cc(Nc2ncc3ccc(OC)c(C)c3n2)cc2[nH]ncc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.40
KDR P35968 8/20 0.40
LCK P06239 1/20 0.39
DPP4 P27487 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
IGF1R P08069 1/20 0.38
KIT P10721 1/20 0.38
PTK2 Q05397 2/20 0.37
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37
APAF1 O14727 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2918651 0.89 KIT (0.38) KDRSMN1; SMN2KITRAB9AJAK2
SCHEMBL2921547 0.85 KIT (0.41) KDRKITNPC1JAK2JAK3
SCHEMBL2912557 0.82 IGF1R (0.45) KDRIGF1RPDGFRBPDGFRAJAK2
SCHEMBL2919831 0.80 IGF1R (0.43) KDRIGF1RPDGFRBPDGFRAJAK2
SCHEMBL2917777 0.77 IGF1R (0.57) KDRSMN1; SMN2IGF1RKDM4ENPC1
SCHEMBL13175537 0.75 KIT (0.39) EGFRKDRSMN1; SMN2KITPTK2
SCHEMBL2918733 0.75 IGF1R (0.41) KDRIGF1RPTK2KDM4EPDGFRB
SCHEMBL2918438 0.74 IGF1R (0.46) KDRIGF1RPTK2PDGFRBPDGFRA
SCHEMBL2920702 0.74 BRAF (0.38) EGFRKDRKITNPC1MAPT
SCHEMBL2919324 0.73 ALDH1A1 (0.40) EGFRKDRSMN1; SMN2KITLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K EGFR 479/4885KDR 1592/4885LCK 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.